Leukemia cells are characterized by differentially expressed leukemia-associated antigens (LAAs). We wondered whether the expression of the LAAs WT1 and RHAMM as well as the T cellular immune response to these LAAs correlated with the clinical outcome of patients suffering from leukemia. We investigated the expression of WT1 and RHAMM at RNA level using qPCR before and after treatment. We concluded that WT1 is a suitable marker for MRD after allogeneic SCT and that a WT1-specific T cell response might contribute to the maintenance of CR.
